Abstract
Coinfections with bacteria or fungi may be a frequent complication of COVID-19, but coinfections with Candida species in COVID-19 patients remain rare. We report the 53-day clinical course of a complicated type-2 diabetes patient diagnosed with COVID-19, who developed bloodstream infections initially due to methicillin-resistant Staphylococcus aureus, secondly due to multidrug-resistant Gram-negative bacteria, and lastly due to a possibly fatal Candida glabrata. The development of FKS-associated pan-echinocandin resistance in the C. glabrata isolated from the patient after 13 days of caspofungin treatment aggravated the situation. The patient died of septic shock shortly before the prospect of receiving potentially effective antifungal therapy. This case emphasizes the importance of early diagnosis and monitoring for antimicrobial drug-resistant coinfections to reduce their unfavorable outcomes in COVID-19 patients.
Original language | English |
---|---|
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | Journal of Fungi |
Volume | 6 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- Bloodstream infection
- Candida glabrata
- Coinfection
- Diabetes
- Echinocandin resistance
- FKS mutation
- SARS-CoV-2